Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03863080
Previous Study | Return to List | Next Study

A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03863080
Recruitment Status : Recruiting
First Posted : March 5, 2019
Last Update Posted : September 27, 2019
Sponsor:
Information provided by (Responsible Party):
Immunovant Sciences GmbH

Brief Summary:
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.

Condition or disease Intervention/treatment Phase
Myasthenia Gravis Drug: RVT-1401 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Blinded
Primary Purpose: Treatment
Official Title: A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
Actual Study Start Date : May 21, 2019
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : February 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Regimen A
RVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
Drug: RVT-1401
Subcutaneous administration of RVT-1401

Experimental: Regimen B
RVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
Drug: RVT-1401
Subcutaneous administration of RVT-1401

Placebo Comparator: Placebo
Placebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
Drug: RVT-1401
Subcutaneous administration of RVT-1401

Drug: Placebo
Subcutaneous administration of Placebo




Primary Outcome Measures :
  1. Assessment of safety by analysis of adverse events (AEs) data [ Time Frame: Weeks 1-18 ]
  2. Change from baseline in levels of total IgG and IgG subclasses (1-4) [ Time Frame: Week 7 ]
  3. Change from baseline in levels of anti-AChR-IgG [ Time Frame: Week 7 ]

Secondary Outcome Measures :
  1. PK Parameters of AUC (0-168 h) after first and last dose [ Time Frame: Weeks 1 and 6 ]
  2. PK maximum concentration (Cmax) after first and last dose [ Time Frame: Weeks 1 and 6 ]
  3. Concentration of RVT-1401 pre-dose (Ctrough) [ Time Frame: Weeks 1-6 ]
  4. Immunogenicity determined by number of participants with positive anti-RVT-1401 antibodies [ Time Frame: Weeks 1-18 ]
  5. Change from baseline in the Quantitative Myasthenia Gravis Score (QMG) Score [ Time Frame: Week 7 ]
  6. Proportion of participants with an improvement on the Quantitative Myasthenia Gravis Score (QMG) score by ≥ 3 points from baseline [ Time Frame: Week 7 ]
  7. Change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score [ Time Frame: Week 7 ]
  8. Proportion of participants with an improvement on the Myasthenia Gravis Activities of Daily Living (MG-ADL) Score by ≥2 points [ Time Frame: Week 7 ]
  9. Change from baseline in the Myasthenia Gravis Composite Score (MGC) score [ Time Frame: Week 7 ]
  10. Proportion of participants with an improvement on the Myasthenia Gravis Composite Score (MGC) Score by ≥3 points [ Time Frame: Week 7 ]
  11. Change from baseline in the Myasthenia Gravis Quality of Life 15 revised Score (MG-QOL 15r) score [ Time Frame: Week 7 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female ≥ 18 years of age.
  2. Myasthenia Gravis Foundation of America (MGFA) Class II-IVa and likely not in need of a respirator for the duration of the study as judged by the Investigator.
  3. QMG score ≥12 at Screening and Baseline.

Other, more specific inclusion criteria are defined in the protocol.

Exclusion Criteria:

  1. Use of rituximab, belimumab, eculizumab or any monoclonal antibody for immunomodulation within 6 months prior to first dosing.
  2. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.
  3. Thymectomy performed < 12 months prior to screening.
  4. Total IgG level <6 g/L (at screening).
  5. Absolute neutrophil count <1500 cells/mm3(at screening).

Other, more specific exclusion criteria are defined in the protocol


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03863080


Contacts
Layout table for location contacts
Contact: Central Study Contact 1-800-797-0414 clinicaltrials@immunovant.com

Locations
Layout table for location information
United States, Alabama
IMC/Diagnostic and Medical Clinic Recruiting
Mobile, Alabama, United States, 36604
Principal Investigator: Hinton         
United States, Arizona
Phoenix Neurological Associates Recruiting
Phoenix, Arizona, United States, 85018
Contact: Study Coordinator         
Principal Investigator: Levine         
United States, California
UC Irvine - MDA ALS and Neuromuscular Center Not yet recruiting
Orange, California, United States, 92868
Principal Investigator: Habib         
United States, Connecticut
Yale School of Medicine Department of Neurology Recruiting
New Haven, Connecticut, United States, 06510
Principal Investigator: Nowak         
United States, Georgia
Rare Disease Research Recruiting
Atlanta, Georgia, United States, 30318
Contact: Study Coordinator         
Principal Investigator: Phan         
United States, Minnesota
University of Minnesota - Department of Neurology Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Study Coordinator         
Principal Investigator: Allen         
United States, New York
University of Buffalo Not yet recruiting
Buffalo, New York, United States, 14260-1660
Contact: Study Coordinator         
Principal Investigator: Silvestri         
Hospital for Special Surgery Recruiting
New York, New York, United States, 10021
Contact: Study Coordinator         
Principal Investigator: Lange         
United States, Pennsylvania
Allegheny Neurological Associates Recruiting
Pittsburgh, Pennsylvania, United States, 15212
Principal Investigator: Small         
United States, Texas
UT Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Study Coordinator         
Principal Investigator: Kahn         
UTSW James W. Aston Ambulatory Care Center - Neurology Clinic Not yet recruiting
Dallas, Texas, United States, 75390
Contact: Jovana Study Coordinator         
Principal Investigator: Shaida         
Canada, Alberta
University of Alberta Hospitals - Division of Pulmonary Medicine Recruiting
Edmonton, Alberta, Canada, T6G 2G3
Contact: Study Coordinator         
Principal Investigator: Siddiqi         
Canada, Ontario
London Health Sciences Centre Recruiting
London, Ontario, Canada, N6G 2V4
Contact: Study Coordinator         
Principal Investigator: Nicolle         
Ottawa Hospital Research Institute Recruiting
Ottawa, Ontario, Canada, K1Y 4E9
Contact: Study Coordinator         
Principal Investigator: Breiner         
University Health Network Toronto General Hospital Recruiting
Toronto, Ontario, Canada, M5G 2C4
Contact: Study Coordinator         
Principal Investigator: Bril         
Canada, Quebec
Montreal Neurological Institute and Hospital Recruiting
Montreal, Quebec, Canada, H3A 2B4
Contact: Study Coordinator         
Principal Investigator: Genge         
Sponsors and Collaborators
Immunovant Sciences GmbH

Layout table for additonal information
Responsible Party: Immunovant Sciences GmbH
ClinicalTrials.gov Identifier: NCT03863080     History of Changes
Other Study ID Numbers: RVT-1401-2002
First Posted: March 5, 2019    Key Record Dates
Last Update Posted: September 27, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Immunovant Sciences GmbH:
IMVT-1401
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Weakness
Myasthenia Gravis
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathologic Processes
Signs and Symptoms
Autoimmune Diseases of the Nervous System
Neuromuscular Junction Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases